The following resolutions were passed at the Extraordinary General Meeting (the "EGM") of Lipidor AB (publ) (the "Company") on 21 May 2024 in Stockholm.
Rights issue of units
The EGM resolved to approve the Board of Directors' resolution on a new issue of units, consisting of shares and warrants of series TO 2, with pre-emption rights for the shareholders, as announced by the Company in press release on 10 April 2024 (the "Rights Issue").
For detailed information on the terms for the Rights Issue and the resolution adopted at this EGM please see the notice that is available on the Company's website, www.lipidor.se.
Complete terms and conditions for the Rights Issue and other information about the Company will be set out in the EU Growth prospectus prepared in connection with the Rights Issue, which is expected to be published on or around 24 May 2024.
Amendments of the Articles of Association
The EGM resolved, in accordance with the Board's proposal, to adopt new Articles of Association. The new Articles of Association contain amended limits for the share capital and the number of shares to enable the Rights Issue. Furthermore, the new Articles of Association contain a provision allowing the General Meeting to be held digitally.
For more information, please contact:
Ola Holmlund, CEO
Telephone: +46 (0) 72 50 70 369
Email: ola.holmlund@lipidor.se
The company's Certified Adviser is Carnegie Investment Bank AB (publ).
About Lipidor AB
Lipidor AB (Nasdaq First North Growth Market: LIPI) (www.lipidor.se) is a pharmaceutical development company with a pipeline of pharmaceutical development projects in preclinical and clinical phases. The company can develop topical medical products for the treatment of diseases such as psoriasis, acne vulgaris, bacterial skin infections and atopic dermatitis by reformulation of proven pharmaceutical substances. Lipidor's priority project is AKP02G2, which focusses on psoriasis.
